SCHEMBL6318295

SCHEMBL6318295

CCCCCCNC(=O)c1c(-c2ccc(-c3cccc(Cl)c3)o2)noc1N

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.50
MAPK1 P28482 1/20 0.50
TP53 P04637 1/20 0.46
HDAC1 Q13547 3/20 0.44
HDAC6 Q9UBN7 3/20 0.44
KDM4E B2RXH2 2/20 0.44
HPGD P15428 1/20 0.44
MAPT P10636 1/20 0.43
ALOX15 P16050 3/20 0.42
GAA P10253 1/20 0.42
EPHX1 P07099 3/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
RAB9A P51151 1/20 0.41
CNR1 P21554 2/20 0.41
HDAC3 O15379 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6316400 1.00 ALDH1A1 (0.50) ALDH1A1MAPK1TP53HDAC1HDAC6
SCHEMBL6314580 1.00 ALDH1A1 (0.50) ALDH1A1MAPK1TP53HDAC1HDAC6
SCHEMBL6318878 0.99 ALDH1A1 (0.51) ALDH1A1MAPK1TP53HDAC1HDAC6
SCHEMBL6315988 0.97 ALDH1A1 (0.51) ALDH1A1MAPK1TP53HDAC1HDAC6
SCHEMBL6316641 0.92 ALDH1A1 (0.58) ALDH1A1MAPK1TP53HDAC1HDAC6
SCHEMBL6323356 0.89 ALDH1A1 (0.46) ALDH1A1MAPK1TP53HDAC1HDAC6
SCHEMBL6318701 0.87 HDAC6 (0.47) ALDH1A1HDAC1HDAC6KDM4EHPGD
SCHEMBL6318133 0.87 HDAC6 (0.47) ALDH1A1HDAC1HDAC6KDM4EHPGD
SCHEMBL6323801 0.87 HDAC6 (0.47) ALDH1A1HDAC1HDAC6KDM4EHPGD
SCHEMBL6321262 0.87 MAPT (0.56) ALDH1A1MAPK1TP53MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 ALDH1A1 4444/4885MAPK1 178/4885TP53 609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.